Vergoeding 2016-2020 voor ATC-subgroep G04CA : Alfa-blokkers
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| G04CA01 Alfuzosine (Xatral ®) | 935.520 | 925.560 | 899.230 | 909.690 | 823.990 |
| G04CA02 Tamsulosine (Omnic ®) | 2.026.700 | 1.982.600 | 2.013.300 | 2.016.700 | 2.049.700 |
| G04CA03 Terazosine (Hytrin ®) | 75.563 | 63.051 | 57.132 | 57.045 | 54.401 |
| G04CA04 Silodosine (Silodyx ®) | 661.350 | 791.800 | 875.920 | 932.480 | 887.380 |
| G04CA52 Tamsulosine met dutasteride (Combodart ®) | 8.118.800 | 8.698.400 | 9.043.200 | 9.080.000 | 7.208.300 |
| G04CA53 Tamsulosine met solifenacine (Vesomni ®) | 2.142.800 | 2.649.100 | 2.961.600 | 3.332.400 | 3.503.900 |
| Totaal | 13.960.733 | 15.110.511 | 15.850.382 | 16.328.315 | 14.527.671 |